|
Chicago Senior Care Services Alzheimer's Care
Clinical Drug Trials For Seniors
Free Memory Loss Screening
Radiant Research Chicago evaluates new research medications for Alzheimer's Disease, Memory Loss, High Cholesterol, High Blood Pressure, Osteoporosis, Depression, Weight Loss and a variety of other medical conditions. The
Alzheimer's Clinical trials offer no-cost, study-related medical services as well as compensation for time and travel expenses to qualified participants.
For information about participation and qualification for current
Alzheimer's Care Studies, call 1.800.494.2227. More information is also available on their website: www.radiantresearch.com
Stroke Survivor Study
We are studying how Stroke Survivors can help manage their stress by writing about their recovery. You may be eligible to participate in our study if
- You are at least six months Post Stroke
- Have no more than mild speech and thinking problems
- Are able to read and write in English
- Are able to travel to the Rehabilitation Institute of Chicago
If you fit these criteria AND you are interested in Writing to Reduce Your Stress, contact Dr. Robert Hartke or Annelouise Tookoian at 312-238-1207. They can also be contacted at rhartke@ric.org or atookoian@ric.org. Transportation can be provided or reimbursed. Assistance with writing will be given if needed.
Northwestern University Clinical Drug Trials
for Seniors
You must live in the Chicago area to participate in these clinical drug trials
for seniors. Contact Stephanie Fields to participate in these
Alzheimer's care studies at: 312-695-2343
ONGOING STUDIES:
1. Alzheimer's Disease Neuroimaging Initiative (ADNI)
STATUS: RECRUITING
ADNI is a nationwide Alzheimer's care study to determine whether imaging of the brain (through MRI, PET or CAT scans) every six months can help predict and monitor the onset and progression of Alzheimer's disease. In addition to neuroimaging,
the study will collect and test blood and, for some participants,
cerebral spinal fluid to determine if biomarkers can predict and
monitor the disease. This Alzheimer's care study is for individuals, age 55 or over, who are in good general health with no memory problems OR are in good general health but have memory problems or concerns OR have a diagnosis of early Alzheimer's disease and are willing and able to undergo the test procedures.
2. AD Genetics Study (Late Onset Alzheimer's Disease)
Sponsored by the National Institute on Aging and the Alzheimer's Association
STATUS: RECRUITING
LOAD is a nationwide study to find genes that play a role in late-life Alzheimer's Disease and understand how they work. This study is for individuals who have 2 or more family members living with Alzheimer's Disease or severe memory loss. Participants
of these Alzheimer's clinical trials will be asked to provide a blood sample, complete a telephone or in person interview, and give permission for their medical records to be reviewed.
3. The Utility of Namenda® in the Treatment of Primary Progressive Aphasia
STATUS: RECRUITING
The purpose of this study is to evaluate whether Namenda ® (memantine), currently an FDA approved medication for Alzheimer's Disease dementia, will reduce decline in PPA patients. Individuals between the ages of 40 and 80, with a current diagnosis of PPA, and who are not currently taking Namenda ® are eligible to participate. Participation includes two treatment conditions; active drug for six months and placebo for six months. Neither the experimenters nor the subjects will know what treatment condition they are in until the entire study is completed. The duration of the study is 15 months, and participants will make five visits.
4. Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study
Sponsored by the National Institute on Aging, Alzheimer's Disease Cooperative Study Group
STATUS: CLOSED
CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). This
Alzheimer's care study is for individuals, age 50 or over, with a diagnosis of probable Alzheimer's disease, mild to moderate severity (e.g., MMSE between 12 and 26 inclusive) who do not require lipid-lowering treatment according to current clinical guidelines. The study design is parallel groups with equal randomization to drug and placebo, and the duration of the study is 18 months.
5. VITAL - VITamins to slow Alzheimer's disease (Homocysteine study)
Sponsored by the National Institute on Aging, Alzheimer's Disease Cooperative Study Group
STATUS: RECRUITING
The purpose of this Alzheimer's care study is to determine whether reduction of homocysteine levels with high-dose folate (folic acid), B6, and B12 supplementation will slow the rate of cognitive decline in persons with Alzheimer's disease. Individuals with a diagnosis of probable Alzheimer's disease, mild to moderate severity (e.g., MMSE between 14 and 26 inclusive) are eligible to participate. Subjects will be divided into two groups: 60% of subjects receive daily high-dose supplements, and 40% receive an identical looking placebo. The duration of treatment is 18 months, and participants will make eight visits.
6. Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease (AD)
Sponsored by the National Institute on Aging, Alzheimer's Disease Cooperative Study Group
STATUS: RECRUITING
The purpose of this Alzheimer's care study is to demonstrate in a randomized, placebo-controlled clinical trial whether chronic valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in their illness. This is a 2-year, multi-center study of subjects with mild to moderate dementia (probable Alzheimer's disease) (e.g., MMSE 10 - 20, inclusive).
7. Assessment Measures for AD Primary Prevention Trials
Sponsored by the National Institute on Aging, Alzheimer's Disease Cooperative Study Group
STATUS: RECRUITMENT COMPLETE
The purpose of this research is to look at the usefulness of new or improved paper and pencil tests in Alzheimer's Disease experiments in subjects. This is a multi-center study is comparing different ways of collecting research information (i.e., in-person, by mail, via computer). Participants in this study are non-demented elderly living independently in the community who are followed on an annual basis. There are currently 21 subjects from the NADC participating in this trial.
You may also direct inquiries regarding our
Alzheimer's care studies in visual attention, functional MRI, sleep/wake rhythms, and taste test to 312-695-2343.
You must live in the Chicagoland area, or be willing to travel to Chicago, to participate in the majority of our
clinical drug trials for seniors.
Contact Stephanie Fields
at 312-695-2343 if you are interested in finding out more
information about a study or to volunteer for any of the Chicago
senior care services.
For more information on Chicagoland Caregivers'
Chicago Senior Care
Services, Alzheimer's Care Services or Alzheimer's Clinical
Trials, please call 312-633-9955 or email: info@livhome.com
|
